![Reading The Room In Oncology Drug Development Frank Bedu-Addo](https://vertassets.blob.core.windows.net/image/b8c562ab/b8c562ab-6199-4660-9c9a-e8214b0afe40/300_200-frank_bedu_addo.png)
-
Cash Needed For Phase 3 Celiac Drug Development6/28/2024
Industry veteran James Sapirstein, CEO of Entero Therapeutics, discusses the company's lead candidate, a treatment for celiac disease, and makes the case for investors and Big Pharma to step up and help bring it across the finish line.
-
Companies To Watch: Volastra Therapeutics6/26/2024
Volastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow.
-
Ten Years In, Project Data Sphere Is Snowballing6/21/2024
Project Data Sphere, an open access data sharing initiative, is expanding into closed access preclinical research and developing AI models that can benefit drug developers.
-
Partnering To Address 'Huge' Opportunities In Women's Health6/14/2024
Nonprofit research foundations can offer scientific expertise and support for biopharmaceutical drug development and clinical programs, helping companies improve new and existing drugs for women.
-
Where Are They Now? Otsuka5/30/2024
Otsuka Precision Health, a new subsidiary focused on digital therapeutics and other tech-enabled solutions for patients, is a continuation of the company's broader mission described by an Otsuka executive in the pages of Life Science Leader eight years ago.
-
Drug Discovery And Development, Powered By Physician Intelligence5/15/2024
For Nuvalent CEO James Porter, physician intelligence is more important than artificial intelligence in discovering and developing new therapies that tackle key unmet needs among cancer patients.
-
Where Are They Now? SQZ Biotech5/1/2024
SQZ Biotech, a novel cell therapy company with Big Pharma backing, is no more. However, the company's science, and its founding CEO, will continue on under new auspices.
-
Reviva Pharma's Novel Funding Approach In Schizophrenia4/25/2024
Reviva Pharma CEO Laxminarayan Bhat, Ph.D. found a novel way to build an investor base for his company during a time when Big Pharma was exiting complicated CNS diseases. Now, Reviva has a late-stage schizophrenia candidate just as CNS is back in vogue.
-
Companies To Watch: OSE Immunotherapeutics4/22/2024
OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.